Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Ibrutinib response in a patient with refractory mixed essential cryoglobulinemia

Published:2023-04 Issue:2 Volume:4 Page:499-500
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Jamali Haya¹^ORCID,Wu David²,Soma Lorinda³^ORCID,Linenberger Michael⁴^ORCID,Wener Mark H.²⁵,Silberstein Lev⁶^ORCID

Affiliation:

1. Department of Medicine Massachusetts General Hospital Boston Massachusetts USA

2. Department of Laboratory Medicine and Pathology Seattle Washington USA

3. Department of Pathology City of Hope Medical Center Duarte California USA

4. Division of Hematology University of Washington Seattle Washington USA

5. Division of Rheumatology University of Washington Seattle Washington USA

6. Fred Hutchinson Cancer Center Seattle Washington USA

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.686

Reference4 articles.

1. Ibrutinib is Effective in Refractory Type II Cryoglobulinemia

2. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients

3. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy

4. Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: BTK inhibitors is effective in type II mixed cryoglobulinemia with wild-type MyD88;Frontiers in Immunology;2024-05-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP